Patents by Inventor James J. Beck
James J. Beck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11944279Abstract: Various embodiments of a swab device, system, and method are provided for measuring and assessing saliva flow in the mouth of a person. In one embodiment, a system includes a swab device and a measuring device. The swab device includes a handle portion and a swab portion, the handle portion being elongated to extend between a proximal end and a distal end. The swab portion is coupled to a distal portion of the handle portion and is sized and configured to collect saliva from the mouth. The measuring device is sized and configured to measure an amount of the saliva collected with the swab portion, the measuring device including a nesting portion integrated therewith. Such nesting portion of the measuring device is sized and configured to receive the proximal end of the handle portion of the swab device to measure the saliva collected therewith.Type: GrantFiled: July 27, 2020Date of Patent: April 2, 2024Assignee: BOKA SCIENCES, INC.Inventors: Grant J. Donovan, Jeffrey A. Stern, Ryan C. Patterson, James A. Malmstrom, Kent F. Beck, Scott D. Miles
-
Patent number: 11919863Abstract: The disclosure is directed to improved methods for preparing substituted quinolinylcyclohexylpropanamide compounds.Type: GrantFiled: December 16, 2021Date of Patent: March 5, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Albert J. Delmonte, Benjamin M. Cohen, Kenneth Joseph Fraunhoffer, Sergei Kolotuchin, Francisco Gonzalez-Bobes, Gregory Louis Beutner, Adam Joseph Freitag, Michael Scott Bultman, Yu Fan, Prantik Maity, Ian Scott Young, Hilary Plake Beck, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky
-
Patent number: 5955274Abstract: DNA sequences from the Internal Transcribed Spacers of the ribosomal RNA gene region are described for different species and strains of Septoria, Pseudocercosporella, Fusarium and Mycosphaerella. Specific primers from within these sequences are identified as being useful for the identification of the fungal isolates using PCR-based techniques.Type: GrantFiled: October 15, 1996Date of Patent: September 21, 1999Assignee: Novartis Finance CorporationInventors: James M. Ligon, James J. Beck
-
Patent number: 5942662Abstract: The present invention provides chemically regulatable DNA sequences capable of regulating transcription of an associated DNA sequence in plants or plant tissues, chimeric constructions containing such sequences, vectors containing such sequences and chimeric constructions, and transgenic plants and plant tissues containing these chimeric constructions. In one aspect, the chemically regulatable DNA sequences of the invention are derived from the 5' region of genes encoding pathogenisis-related (PR) proteins. The present invention also provides anti-pathogenic sequences derived from novel cDNAs coding for PR proteins which can be genetically engineered and transformed into plants to confer enhanced resistance to disease.Type: GrantFiled: November 14, 1997Date of Patent: August 24, 1999Assignee: Novartis Finance CorporationInventors: John A. Ryals, Christian T. Harms, Leslie B. Friedrich, James J. Beck, Scott J. Uknes, Eric R. Ward
-
Patent number: 5716849Abstract: The present invention is directed to the production of a polyketide antibiotic such as soraphen in a host via recombinant expression of the polypeptides needed to biologically synthesize the polyketide antibiotic. Polyketide synthase (PKS) genes encoding polypeptides necessary to synthesize soraphen are provided, along with methods for identifying and isolating the PKS genes needed to recombinantly biosynthesize any desired polyketide antibiotic. The cloned PKS genes may be transformed and expressed in a desired host organisms to produce soraphen for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of soraphen.Type: GrantFiled: December 14, 1996Date of Patent: February 10, 1998Assignee: Novartis Finance CorporationInventors: James M. Ligon, Thomas Schupp, James J. Beck, Dwight S. Hill, Snezana Neff, John A. Ryals
-
Patent number: 5654414Abstract: The present invention provides chemically regulatable DNA sequences capable of regulating transcription of an associated DNA sequence in plants or plant tissues, chimeric constructions containing such sequences, vectors containing such sequences and chimeric constructions, and transgenic plants and plant tissues containing these chimeric constructions. In one aspect, the chemically regulatable DNA sequences of the invention are derived from the 5' region of genes encoding pathogenisis-related (PR) proteins. The present invention also provides anti-pathogenic sequences derived from novel cDNAs coding for PR proteins which can be genetically engineered and transformed into plants to confer enhanced resistance to disease.Type: GrantFiled: May 19, 1995Date of Patent: August 5, 1997Assignee: Novartis Finance CorporationInventors: John A. Ryals, James J. Beck, Leslie B. Friedrich
-
Patent number: 5650505Abstract: The present invention provides chemically regulatable DNA sequences capable of regulating transcription of an associated DNA sequence in plants or plant tissues, chimeric constructions containing such sequences, vectors containing such sequences and chimeric constructions, and transgenic plants and plant tissues containing these chimeric constructions. In one aspect, the chemically regulatable DNA sequences of the invention are derived from the 5' region of genes encoding pathogenisis-related (PR) proteins. The present invention also provides anti-pathogenic sequences derived from novel cDNAs coding for PR proteins which can be genetically engineered and transformed into plants to confer enhanced resistance to disease.Type: GrantFiled: May 24, 1995Date of Patent: July 22, 1997Assignee: Novartis CorporationInventors: John A. Ryals, Danny C. Alexander, James J. Beck, John H. Duesing, Robert M. Goodman, Leslie B. Friedrich, Christian Harms, Frederich Meins, Jr., Alice Montoya, deceased, Mary B. Moyer, Jean-Marc Neuhaus, George B. Payne, Christoph Sperisen, Jeffrey R. Stinson, Scott J. Uknes, Eric R. Ward, Shericca C. Williams
-
Patent number: 5614395Abstract: The present invention provides chemically regulatable DNA sequences capable of regulating transcription of an associated DNA sequence in plants or plant tissues, chimeric constructions containing such sequences, vectors containing such sequences and chimeric constructions, and transgenic plants and plant tissues containing these chimeric constructions. In one aspect, the chemically regulatable DNA sequences of the invention are derived from the 5' region of genes encoding pathogenisis-related (PR) proteins. The present invention also provides anti-pathogenic sequences derived from novel cDNAs coding for PR proteins which can be genetically engineered and transformed into plants to confer enhanced resistance to disease.Type: GrantFiled: January 13, 1994Date of Patent: March 25, 1997Assignee: Ciba-Geigy CorporationInventors: John A. Ryals, Danny C. Alexander, James J. Beck, John H. Duesing, Robert M. Goodman, Leslie B. Friedrich, Christian Harms, Frederich Meins, Jr., Alice Montoya, deceased, Mary B. Moyer, Jean-Marc Neuhaus, George B. Payne, Christoph Sperisen, Jeffrey R. Stinson, Scott J. Uknes, Eric R. Ward, Shericca C. Williams
-
Patent number: 5585238Abstract: DNA sequences from the Internal Transcribed Spacer of the ribosomal RNA gene region are described for different species and strains of Septoria, Pseudocercosporella and Mycosphaerella. Specific primers from within these sequences are identified as being useful for the identification of the fungal isolates using PCR-based techniques.Type: GrantFiled: April 25, 1994Date of Patent: December 17, 1996Assignee: Ciba-Geigy CorporationInventors: James M. Ligon, James J. Beck